Metastatic Breast Cancer

Women diagnosed with advanced breast cancer appeared more likely than those with earlier-stage breast cancer to have pre-existing cardiovascular disease, according to results of a retrospective study.

In this episode of Meeting Mic, we bring you the highlights and insights from the San Antonio Breast Cancer Symposium 2024, as well as Healio’s top headlines from the meeting.

SAN ANTONIO — In this video, Shimoli Barot, MD, discusses the results of a study observing exceptional treatment response in patients with metastatic breast cancer presented at San Antonio Breast Cancer Symposium.

SAN ANTONIO — The addition of palbociclib to standard care extended median PFS for patients with hormone receptor-positive, HER2-positive metastatic breast cancer, according to study results presented at San Antonio Breast Cancer Symposium.

SAN ANTONIO — The addition of pyrotinib to first-line trastuzumab and docetaxel improved PFS among patients with HER2-positive metastatic breast cancer, according to study results presented at San Antonio Breast Cancer Symposium.

The detection of specific genomic alterations in circulating tumor DNA appeared linked to poorer outcomes among women with metastatic breast cancer, according to study results.

The addition of inavolisib to palbociclib and fulvestrant more than doubled PFS for certain patients with advanced breast cancer, according to results of a randomized phase 3 trial.

Innovative dosing strategies are warranted to improve the well-being of individuals with metastatic breast cancer, according to a patient advocate-led study published in JCO Oncology Practice.

The FDA approved inavolisib as part of combination therapy for certain adults with breast cancer.

Trastuzumab deruxtecan showed substantial and durable overall and intracranial clinical activity in patients with HER2-positive metastatic breast cancer, according to results from the DESTINYBreast-12 trial presented at ESMO Congress.